- Pharma Industry
- 1 min read
Danish economy gets boost from weight-loss drug maker
Novo Nordisk's net profit soared by 51 percent in 2023 to 83.7 billion kroner ($12.1 billion) as sales of diabetes medication Ozempic and obesity drug Wegovy have boomed.
National data agency Statistics Denmark said the sector's contribution to growth amounted to 1.9 percent.
"If it is deducted from GDP growth, you get a big zero," the agency's chief accounting consultant, Jonas Dan Petersen, said on X (formerly Twitter).
Novo Nordisk's net profit soared by 51 percent in 2023 to 83.7 billion kroner ($12.1 billion) as sales of diabetes medication Ozempic and obesity drug Wegovy have boomed.
The drug maker's shares also surged last year, turning Novo Nordisk into Europe's largest company by market capitalisation.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions